HAIC-FOLFOX

DRUG2 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, West China Hospital

Conditions

Hepato Cellular Carcinoma (HCC)Resectable Hepatocellular Carcinoma

Phase 2

Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

Tianjin Medical University Cancer Institute and HospitalResectable Hepatocellular Carcinoma

Start: 2022-08-23End: 2025-09-01Target: 60Updated: 2022-08-29

PD-L1 Antibody + Bevacizumab With Hepatic Arterial Infusion Chemotherapy for Advanced HCC

RecruitingNCT06742424

West China HospitalHepato Cellular Carcinoma (HCC)

Start: 2024-10-01End: 2027-07-30Target: 36Updated: 2024-12-19

Related Papers

Sintilimab combined with lenvatinib versus hepatic artery infusion chemotherapy (HAIC) for neoadjuvant treatment of resectable hepatocellular carcinoma with high risk of recurrence: A prospective, two-arm, randomized, phase II clinical study.

Journal of Clinical Oncology2026-01-10

Sintilimab combined with lenvatinib versus hepatic artery infusion chemotherapy (HAIC) for neoadjuvant treatment of resectable primary hepatocellular carcinoma with high risk of recurrence: A prospective, two-arm, randomized, phase II clinical study.

Journal of Clinical Oncology2025-05-28